Platinum chemotherapy plus immunotherapy is the most widely used first-line treatment for advanced NSCLC without epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) and ROS-1 rearrangement [8]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.